Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 804 participants.
Also called NCT04289285
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 804 participants
- Registry
-
NCT04289285
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04289285. Randomized; quadruple masking; primary purpose treatment. Start 2020-04-29 (actual); primary completion 2022-02-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- IBI306 450mg SC Q4W
- Intervention (Drug)
- Placebo SC Q4W
- Intervention (Drug)
- IBI306 600mg SC Q6W
- Intervention (Other)
- Placebo SC Q6W
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Record details
- Record id
cardio:ct-nct04289285- Content hash
2326643068d935775af9a64ed570adb15ed4b444bc5f7bfb8304b3556acc4b49